Back to top

MAVENCLAD® (cladribine tablets) for RRMS

tablets
17 August 2018

PBAC recommends PBS listing subject to Federal Health Minister’s approval

MS Australia reports today that MAVENCLAD® (cladribine tablets) has been recommended for listing on the Pharmaceutical Benefits Scheme (PBS) for relapsing remitting MS (RRMS), by the Pharmaceutical Benefits Advisory Committee (PBAC), subject to final approval by the Federal Health Minister.

Previously, MAVENCLAD® was registered for use in Australia by the Therapeutic Goods Administration (TGA), for the treatment of patients with RRMS, to reduce inflammation in the nervous system caused by MS. It is administered in two treatment courses, over two years; each treatment course consists of two treatment weeks.  No further treatment is required in years 3 and 4.

Whilst the PBAC have recommended MAVENCLAD® for RRMS, its listing on the PBS is still subject to approval by the Federal Health Minister.

More information is available from: http://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/pbac-outcomes

http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2018-07/positive-recommendations-07-2018.pdf (See page 5:)